全文获取类型
收费全文 | 2647篇 |
免费 | 148篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 67篇 |
儿科学 | 241篇 |
妇产科学 | 24篇 |
基础医学 | 245篇 |
口腔科学 | 49篇 |
临床医学 | 152篇 |
内科学 | 566篇 |
皮肤病学 | 62篇 |
神经病学 | 212篇 |
特种医学 | 96篇 |
外科学 | 455篇 |
综合类 | 136篇 |
一般理论 | 1篇 |
预防医学 | 91篇 |
眼科学 | 119篇 |
药学 | 117篇 |
中国医学 | 6篇 |
肿瘤学 | 166篇 |
出版年
2022年 | 21篇 |
2021年 | 61篇 |
2020年 | 28篇 |
2019年 | 51篇 |
2018年 | 55篇 |
2017年 | 35篇 |
2016年 | 40篇 |
2015年 | 83篇 |
2014年 | 100篇 |
2013年 | 142篇 |
2012年 | 137篇 |
2011年 | 170篇 |
2010年 | 101篇 |
2009年 | 86篇 |
2008年 | 113篇 |
2007年 | 138篇 |
2006年 | 137篇 |
2005年 | 87篇 |
2004年 | 82篇 |
2003年 | 86篇 |
2002年 | 89篇 |
2001年 | 51篇 |
2000年 | 53篇 |
1999年 | 61篇 |
1998年 | 59篇 |
1997年 | 31篇 |
1996年 | 30篇 |
1995年 | 18篇 |
1994年 | 23篇 |
1993年 | 20篇 |
1992年 | 45篇 |
1991年 | 44篇 |
1990年 | 55篇 |
1989年 | 46篇 |
1988年 | 39篇 |
1987年 | 29篇 |
1986年 | 22篇 |
1985年 | 25篇 |
1984年 | 26篇 |
1983年 | 19篇 |
1979年 | 21篇 |
1978年 | 15篇 |
1977年 | 13篇 |
1976年 | 21篇 |
1975年 | 14篇 |
1974年 | 19篇 |
1973年 | 18篇 |
1972年 | 16篇 |
1969年 | 19篇 |
1968年 | 23篇 |
排序方式: 共有2805条查询结果,搜索用时 0 毫秒
71.
Dinesh Raj Rakesh Lodha Aparna Mukherjee Tavpritesh Sethi Anurag Agrawal Sushil Kumar Kabra 《Indian pediatrics》2014,51(2):105-111
Objective
To determine whether fractional exhaled nitric oxide (FENO) has a utility as a diagnostic or predictive maker in acute exacerbations of asthma in children.Design
Analysis of data collected in a pediatric asthma cohort.Setting
Pediatric Chest Clinic of a tertiary care hospitalMethods
A cohort of children with asthma was followed up every 3 months in addition to any acute exacerbation visits. Pulmonary function tests (PFT) and FENO were obtained at all visits. We compared the FENO values during acute exacerbations with those at baseline and those during the follow up.Results
243 asthmatic children were enrolled from August 2009 to December 2011 [mean (SD) follow up — 434 (227) days]. FENO during acute exacerbations was not different from FENO during follow up; however, FENO was significantly higher than personal best FENO during follow up (P < 0.0001). FENO during acute exacerbation did not correlate with the severity of acute exacerbation (P=0.29). The receiver operating characteristics curve for FENO as a marker for acute exacerbation had an area under the curve of 0.59. Cut-off of 20 ppb had a poor sensitivity (44%) and specificity (68.7%) for acute exacerbation.Conclusions
FENO levels during acute exacerbation increase from their personal best levels. However, no particular cut off could be identified that could help in either diagnosing acute exacerbation or predicting its severity. 相似文献72.
Safinur Atay Samagya Banskota Jennifer Crow Geetika Sethi Lori Rink Andrew K. Godwin 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(2):711-716
During tumor development, constant interplay occurs between tumor cells and surrounding stromal cells. We report evidence that gastrointestinal stromal tumor (GIST) cells invade the interstitial stroma through the release of the oncogenic protein tyrosine kinase (KIT)-containing exosomes, which triggers the phenotypic conversion of progenitor smooth muscle cells to tumor-promoting cells. These recipient cells display morphologic changes and acquire tumor-associated phenotypes, including enhanced adhesion to extracellular matrix proteins, activation of intracellular pathways downstream of KIT, expression of Interstitial Cell of Cajal–like markers, and release of various matrix metalloproteinases (MMPs), particularly MMP1. This report shows stimulation of MMP1 production by stromal cells via uptake of tumor-derived exosomes, which leads to tumor cell invasion. Exosomes derived from GIST patients but not healthy donors show enhanced MMP1 secretion by smooth muscle cells and tumor cell invasion, whereas selective blocking of exosome-mediated MMP1 secretion decreases tumor invasiveness. Our study indicates that exosome release and subsequent MMP1 induction creates a positive feedback mechanism established between tumor and stromal cells that drives GIST development and offers unique insights for potential therapeutic strategies to block GIST progression and metastatic spread.With the ultimate goal of fulfilling their needs for exogenous supply of growth factors, chemokines, cytokines, and matrix-degrading enzymes, tumor cells communicate with their surrounding stroma using several intercellular communication mechanisms (1, 2). In the last decade, various tumors have been shown to rely on the release of bioactive membrane vesicles known as exosomes (3). Tumor cells of various origins constitutively release these vesicles, which are believed to be important in the processes of malignant transformation and tumor progression. Exosomes share certain common characteristics, including their shape, size, density, and general protein composition (3). Their effects are mediated via transfer of cargo that comprises an array of proteins (4), RNA (5), and mitochondrial DNA (6). Accordingly, their role as mediators in tumor progression has been the focus of several recent studies (7, 8). However, the majority of these studies focused on human malignancies of epithelial origin (i.e., carcinomas), whereas little attention has been given to the tumor microenvironment associated with malignancies of mesenchymal origin (i.e., sarcomas).Sarcomas represent an interesting and unique tumor type in which cancer cells of mesenchymal origin are surrounded by stromal cells of the same origin. The focus of this study is on the most common mesenchymal tumor of the digestive tract, gastrointestinal stromal tumor (GIST) (9). Approximately 75% of GISTs contain oncogenic mutations in the receptor tyrosine kinase c-KIT [normal cellular homolog of the viral oncoprotein v-Kit (v-Kit, Hardy Zuckerman 4 feline sarcoma viral oncogene homolog)] (10, 11), which plays a central role in the pathogenesis of this disease (10, 12). GISTs are believed to arise from the Interstitial Cells of Cajal (ICCs) (13), the pacemaker cells of the gastrointestinal tract, or interstitial mesenchymal precursor stem cells (14). This similarity between GISTs and ICCs is further borne out by the expression of the KIT protein (also called CD117) in nonneoplastic ICC and most GISTs (11). The identification of a fundamental hallmark of the biology of GISTs (i.e., gain-of-function KIT mutations) resulted in the rapid transformation of the treatment paradigm for this tumor type (15, 16). Small molecule tyrosine kinase inhibitors, most notably imatinib mesylate (also known as Gleevec), have been developed and were found to be effective in the treatment of GISTs (16–18). However, the median time to recurrence for patients with metastatic GIST receiving imatinib is only 2 y. Although much is known about the molecular genetic features of GIST, the importance of their interactions with the stromal microenvironment during metastasis has received little attention. Therefore, we investigated the role of exosomes in mediating the complex interplay between tumor and stroma during progression. We report evidence that (i) GIST cells secrete a high number of oncogenic KIT-containing exosomes, (ii) stromal cell uptake of GIST-derived exosomes promotes the generation of ICC-like cells and induce tumor invasiveness, and (iii) circulating exosomes from GIST patients induce matrix metalloproteinase 1 (MMP1) secretion by host stromal cells. 相似文献
73.
Sleep and Breathing - Patients with obstructive sleep apnea (OSA) may experience apneas and hypopneas primarily during stage R (REM) sleep when end-expiratory lung volume (EELV) reaches its nadir.... 相似文献
74.
Rupesh Raina Shyam Polaconda Nikhil Nair Ronith Chakraborty Sidharth Sethi Vinod Krishnappa Gaurav Kapur Maroun Mhanna Kirsten Kusumi 《Journal of clinical hypertension (Greenwich, Conn.)》2020,22(6):1059-1069
The morbidity and mortality of adult and pediatric chronic kidney disease (CKD) and end‐stage renal disease (ESRD) populations are mainly driven by cardiovascular disease (CVD). Improving CVD outcomes focuses on risk assessment of factors including diastolic blood pressure (DBP), systolic blood pressure (SBP), left ventricular mass index (LVMI), pulse pressure (PP), and pulse pressure index (PPi), which is calculated as PP/SBP. These markers are also proven predictors of CKD progression; however, their role in children has not been established. This study aims to evaluate the relationship between PP, PPi, ambulatory arterial stiffness index (AASI), and proteinuria with kidney function in pediatric CKD patients; it is a retrospective analysis of 620 patients (1‐16 years) from the NIDDK Chronic Kidney Disease in Children (CKiD) registry. The authors analyzed data for three separate cohorts: an overall CKD as well as immunological versus non‐immunological cause for CKD groups. An inverse relationship was found between SBP, DBP, and PP with iGFR and LVMI in the overall CKD group. Our immunological CKD subgroup showed significantly higher serum creatinine, SBP, DBP, and PP values with significantly lower serum albumin levels compared to the non‐immunological group. There were no significant differences with iohexol‐based glomerular filtration rate (iGFR), LVMI, PPi, or high‐sensitivity C‐reactive protein (hs‐CRP) between the two groups. A subgroup analysis demonstrated that SBP, DBP, and PP all correlated significantly with LVMI in the immunological CKD patients but not the non‐immunological subgroup. Additionally, AASI data in the overall CKD population were significantly correlated with PP, PPi, and DBP. This study is one of the first to correlate noninvasive measurements of vascular compliance including PP, PPi, and AASI with iGFR and LVMI in a pediatric CKD cohort. Improving our understanding of surrogate markers for early CVD is integral to improving the care of pediatric CKD population as these patients have yet to develop the hard end points of ESRD, heart failure, myocardial infarction, or stroke. 相似文献
75.
Karve S Werner ME Sukumar R Cummings ND Copp JA Wang EC Li C Sethi M Chen RC Pacold ME Wang AZ 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(21):8230-8235
One of the promises of nanoparticle (NP) carriers is the reformulation of promising therapeutics that have failed clinical development due to pharmacologic challenges. However, current nanomedicine research has been focused on the delivery of established and novel therapeutics. Here we demonstrate proof of the principle of using NPs to revive the clinical potential of abandoned compounds using wortmannin (Wtmn) as a model drug. Wtmn is a potent inhibitor of phosphatidylinositol 3' kinase-related kinases but failed clinical translation due to drug-delivery challenges. We engineered a NP formulation of Wtmn and demonstrated that NP Wtmn has higher solubility and lower toxicity compared with Wtmn. To establish the clinical translation potential of NP Wtmn, we evaluated the therapeutic as a radiosensitizer in vitro and in vivo. NP Wtmn was found to be a potent radiosensitizer and was significantly more effective than the commonly used radiosensitizer cisplatin in vitro in three cancer cell lines. The mechanism of action of NP Wtmn radiosensitization was found to be through the inhibition of DNA-dependent protein kinase phosphorylation. Finally, NP Wtmn was shown to be an effective radiosensitizer in vivo using two murine xenograft models of cancer. Our results demonstrate that NP drug-delivery systems can promote the readoption of abandoned drugs such as Wtmn by overcoming drug-delivery challenges. 相似文献
76.
77.
78.
79.
PS Spencer K Vandemaele M Richer VS Palmer S Chungong M Anker Y Ayana ML Opoka BN Klaucke A Quarello JK Tumwine 《African health sciences》2013,13(2):183-204
Background
Nodding Syndrome is a seizure disorder of children in Mundri County, Western Equatoria, South Sudan. The disorder is reported to be spreading in South Sudan and northern Uganda.Objective
To describe environmental, nutritional, infectious, and other factors that existed before and during the de novo 1991 appearance and subsequent increase in cases through 2001.Methods
Household surveys, informant interviews, and case-control studies conducted in Lui town and Amadi village in 2001–2002 were supplemented in 2012 by informant interviews in Lui and Juba, South Sudan.Results
Nodding Syndrome was associated with Onchocerca volvulus and Mansonella perstans infections, with food use of a variety of sorghum (serena) introduced as part of an emergency relief program, and was inversely associated with a history of measles infection. There was no evidence to suggest exposure to a manmade neurotoxic pollutant or chemical agent, other than chemically dressed seed intended for planting but used for food. Food use of cyanogenic plants was documented, and exposure to fungal contaminants could not be excluded.Conclusion
Nodding Syndrome in South Sudan has an unknown etiology. Further research is recommended on the association of Nodding Syndrome with onchocerciasis/mansonelliasis and neurotoxins in plant materials used for food. 相似文献80.
The endothelial progenitor cell (EPC) capture stent is an innovative device that makes use of the ability of bone marrow-derived EPCs to migrate to injured arterial segments to facilitate healing. The EPC antibody surface, consisting of a covalently coupled polysaccharide intermediate coating with anti-human CD34 antibodies, is attached to a stainless steel stent. Upon stent placement, the anti-human CD34 antibodies will attract circulating EPCs, which are expected to develop into mature functional endothelium. This accelerated healing strategy aims to lower the risk of restenosis and stent thrombosis, as well as obviate prolonged dual antiplatelet therapy. Since the first-in-man study in 2003, a number of small-to-medium size registry and postmarketing studies that confirmed the good safety profile of the EPC capture stent have been published. However, due to lack of large-scale randomized trials, its effectiveness, compared with bare metal stents and drug-eluting stents, cannot be ascertained. Based on restudy angiographic data, instent late loss was approximately 0.7-0.9 mm, which compares unfavorably with that of drug-eluting stents. In order to improve the effectiveness of the EPC capture stent in reducing restenosis-while maintaining its pro-healing property-a bioengineered sirolimus-eluting stent known as the Combo stent was recently designed to combine the EPC capture technology with the abluminal elution of sirolimus. Data from animal studies have been encouraging. The first-in-man study of the Combo stent has been completed and results were presented. (J Interven Cardiol 2012;25:493-500). 相似文献